Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Company Overview

Enzon Pharmaceuticals, Inc., headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology. Through strategic partnerships and licensing agreements, Enzon expanded the global reach of its oncology portfolio and supported the development of additional PEGylated molecules targeting cancer and hematologic disorders.

Enzon’s PEGylation platform has been applied to multiple pipeline candidates at various stages of clinical development. Research efforts have included novel conjugates designed to selectively target malignant cells while reducing dosing frequency. By collaborating with academic institutions and other biopharmaceutical companies, Enzon advanced its programs across North America, Europe and Asia.

Over its history, Enzon Pharmaceuticals has maintained a leadership team with expertise in drug development, regulatory affairs and commercial strategy, guiding the company through licensing, clinical trials and lifecycle management of its products. Its pioneering work in PEGylation continues to influence the broader biopharmaceutical industry.

Key Stats

• Today's Range: $5.75 to $6.07
• 50-Day Range: $4.99 to $7.80
• 52-Week Range: $1.50 to $12.99
• Volume: 5,412 shs
• Average Volume: 1,319 shs
• Market Capitalization: $4.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Enzon Pharmaceuticals Stock Analysis - MarketRank™

Enzon Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Enzon Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Enzon Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enzon Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enzon Pharmaceuticals has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Enzon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Enzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enzon Pharmaceuticals has recently increased by 20.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enzon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Enzon Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Enzon Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Enzon Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enzon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.40% of the stock of Enzon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Enzon Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ENZN
• Previous Symbol: NASDAQ:ENZN
• CIK: 727510
• Web: www.enzon.com
• Phone: (732) 980-4500
• Fax: 732-980-4585
• Employees: N/A
• Year Founded: 1981

Profitability

• EPS (Trailing Twelve Months): ($6.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.41 million
• Net Margins: N/A
• Pretax Margin: 6.52%
• Return on Equity: -21.54%
• Return on Assets: -7.22%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 2.01
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 143.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $256.94 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 740,000
• Free Float: 739,000
• Market Cap: $4.31 million
• Optionable: Not Optionable
• Beta: -0.03